NCT06002477 Attentional Mechanisms in SCD
| NCT ID | NCT06002477 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Subjective Cognitive Decline |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-06 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 80 participants in total. It began in 2025-06-06 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.
Eligibility Criteria
Inclusion Criteria: 1. age ≥ 55 2. Montreal Cognitive Assessment (MoCA) \> 25 AND Global Deterioration Scale (GDS) rating \< 3 3. Non-smokers Exclusion Criteria: 1. medical contraindications to the drug challenge 2. primary neurological disorder (such as stroke, epilepsy, etc.)
Contact & Investigator
Paul Newhouse, MD
STUDY DIRECTOR
Vanderbilt University Medical Center
Frequently Asked Questions
Who can join the NCT06002477 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Subjective Cognitive Decline. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06002477 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06002477 currently recruiting?
Yes, NCT06002477 is actively recruiting participants. Contact the research team at kimberly.albert@vumc.org for enrollment information.
Where is the NCT06002477 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06002477 clinical trial?
NCT06002477 is sponsored by Vanderbilt University Medical Center. The principal investigator is Paul Newhouse, MD at Vanderbilt University Medical Center. The trial plans to enroll 80 participants.